

RECEIVED

Ark
Therapeutics

2005 DEC 13 P 5 02


OFFICE OF INTERNATIONAL
CORPORATE FINANCE

Ark Therapeutics Group Plc
79 New Cavendish Street
London W1W 6XB
Tel: +44 (0)20 7388 7722
Fax: +44 (0)20 7388 7805
www.arktherapeutics.com

7 December 2005

BY COURIER

US Securities and Exchange Commission
Division of Corporate Finance
Office of International Corporate Finance
Mail Stop 3-2
450 Fifth Street NW
Washington DC 20549
USA



05013230

SUPPL

Ark Therapeutics Group plc, Rule 12g3-2(b) Exemption, File No. 82-34804

To whom it may concern:

Please find enclosed information and/or documents furnished on behalf of Ark Therapeutics Group plc, Rule 12g3-2(b) File No. 82-34804, submitted pursuant to paragraph (b)(1)(iii) of Rule 12g3-2, which information shall not be deemed "filed" with the SEC or otherwise subject to the liabilities of Section 18 of the US Securities Exchange Act of 1934.

Sincerely,

N.R.L. Plummer

Nick Plummer
General Counsel & Company Secretary
Ark Therapeutics Group plc

PROCESSED

DEC 14 2005

THOMSON
FINANCIAL

dlw/13



Kuopio

London

Registered Office:
79 New Cavendish Street
London W1W 6XB, UK
Registered in England 4313987

1.	DOCUMENTS MADE PUBLIC PURSUANT TO LAWS OF ENGLAND AND WALES SINCE NOVEMBER 1, 2005
1.1	Form 363s Annual return dated November 2, 2005
1.2	Form 88(2) - Return of Allotment of Shares dated November 17, 2005
1.3	Form 88(2) - Return of Allotment of Shares dated November 17, 2005
1.4	Form 88(2) - Return of Allotment of Shares dated November 18, 2005
1.5	Form 88(2) - Return of Allotment of Shares dated December 6, 2005
2.	DOCUMENTS FILED WITH THE UKLA OR THE LSE (AND MADE PUBLIC THEREBY) SINCE NOVEMBER 1, 2005
2.1	Miscellaneous Notifications filed with The London Stock Exchange
2.1.1	Announcement dated, November 3, 2005 regarding Grant for New Facility
2.1.2	Announcement dated, December 5, 2005 regarding Blocklisting Interim Review
2.1.3	Announcement dated, December 5, 2005 regarding Blocklisting Interim Review
3.	PRESS RELEASES SINCE NOVEMBER 1, 2005
3.1	Press release dated November 3, 2005 regarding Grant for New Facility (see 2.1.1 above)

Company Name

ARK THERAPEUTICS GROUP PLC **363s Annual Return**

Company Type
Public Limited Company

Company Number
4313987

Information extracted from
Companies House records on
8th October 2005

- > Please check the details printed in blue on this statement.
- > If any details are wrong, strike them through and write the correct details in the "Amended details" column.
- > Please use black pen and write in capitals.

Section 1: Company details

Ref: 4313987/09/28

	Current details	Amended details																
<p>> Registered Office Address <i>If any of the details are wrong, strike them through and fill in the correct details in the "Amended details" column.</i></p>	<p>79 New Cavendish Street London W1W 6XB</p>	<p>Address</p> <p>_____</p> <p>_____</p> <p>_____</p> <p>UK Postcode _ _ _ _ _</p>																
<p>> Register of Members <i>If any of the details are wrong, strike them through and fill in the correct details in the "Amended details" column.</i></p>	<p>Address where the Register is held The Registry 34 Beckenham Road Beckenham Kent BR3 4TU</p>	<p>Address</p> <p>_____</p> <p>_____</p> <p>_____</p> <p>UK Postcode _ _ _ _ _</p>																
<p>> Register of Debenture Holders <i>If any of the details are wrong, strike them through and fill in the correct details in the "Amended details" column.</i></p>	<p>Not Applicable</p>	<p>Address</p> <p>_____</p> <p>_____</p> <p>_____</p> <p>UK Postcode _ _ _ _ _</p>																
<p>> Principal Business Activities <i>If any of the details are wrong, strike them through and fill in the correct details in the "Amended details" column.</i></p>	<table border="1"> <thead> <tr> <th>SIC Code</th> <th>Description</th> </tr> </thead> <tbody> <tr> <td>7310</td> <td>R & D on nat sciences & engineering</td> </tr> </tbody> </table>	SIC Code	Description	7310	R & D on nat sciences & engineering	<table border="1"> <thead> <tr> <th>SIC CODE</th> <th>Description</th> </tr> </thead> <tbody> <tr> <td>_____</td> <td>_____</td> </tr> </tbody> </table>	SIC CODE	Description	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
SIC Code	Description																	
7310	R & D on nat sciences & engineering																	
SIC CODE	Description																	
_____	_____																	
_____	_____																	
_____	_____																	
_____	_____																	
_____	_____																	
<p>> <i>Please enter additional principal activity code(s) in "Amended details" column. See notes for guidance for list of activity codes.</i></p>																		

> Director

If any of the details for this person are wrong, strike them through and fill in the correct details in the "Amended details" column.

Name

Peter Stephen KEEN

Address

79 New Cavendish Street
London
W1W 6XB

Date of birth 27/08/1957

Nationality British

Occupation Chartered Accountant

Particulars of a new Director must be notified on form 288a.

Name

Tick this box if this address is a service address for the beneficiary of a Confidentiality Order granted under section 723B of the Companies Act 1985.

Address

UK Postcode _ _ _ _ _

Date of birth _ _ / _ _ / _ _ _ _

Nationality _____

Occupation _____

Date of change _ _ / _ _ / _ _ _ _

Date Peter Stephen KEEN ceased to be director (if applicable)

 _ _ / _ _ / _ _ _ _

> Director

If any of the details for this person are wrong, strike them through and fill in the correct details in the "Amended details" column.

Name

Nigel Richard PARKER

Address

79 New Cavendish Street
London
W1W 6XB

Date of birth 02/08/1953

Nationality British

Occupation Company Director

Particulars of a new Director must be notified on form 288a.

Name

Tick this box if this address is a service address for the beneficiary of a Confidentiality Order granted under section 723B of the Companies Act 1985.

Address

UK Postcode _ _ _ _ _

Date of birth _ _ / _ _ / _ _ _ _

Nationality _____

Occupation _____

Date of change _ _ / _ _ / _ _ _ _

Date Nigel Richard PARKER ceased to be director (if applicable)

 _ _ / _ _ / _ _ _ _

> **Director**

If any of the details for this person are wrong, strike them through and fill in the correct details in the "Amended details" column.

Name
Wolfgang PLISCHKE

This is a service address for the beneficiary of a Confidentiality Order.

Address
79 New Cavendish Street
London
W1W 6XB

Date of birth 15/09/1951

Nationality German

Occupation Company Director

Particulars of a new Director must be notified on form 288a.

Name

Tick this box if this address is a service address for the beneficiary of a Confidentiality Order granted under section 723B of the Companies Act 1985.

Address

UK Postcode _ _ _ _ _ _ _

Date of birth _ _ / _ _ / _ _ _ _

Nationality _____

Occupation _____

Date of change _ _ / _ _ / _ _ _ _

Date Wolfgang PLISCHKE ceased to be director (if applicable)

 _ _ / _ _ / _ _ _ _

> **Director**

If any of the details for this person are wrong, strike them through and fill in the correct details in the "Amended details" column.

Name
David Norman PRINCE

This is a service address for the beneficiary of a Confidentiality Order.

Address
79 New Cavendish Street
London
W1W 6XB

Date of birth 24/06/1951

Nationality British

Occupation Consultant

Particulars of a new Director must be notified on form 288a.

Name

Tick this box if this address is a service address for the beneficiary of a Confidentiality Order granted under section 723B of the Companies Act 1985.

Address

UK Postcode _ _ _ _ _ _ _

Date of birth _ _ / _ _ / _ _ _ _

Nationality _____

Occupation _____

Date of change _ _ / _ _ / _ _ _ _

Date David Norman PRINCE ceased to be director (if applicable)

 _ _ / _ _ / _ _ _ _

> **Director**
If any of the details for this person are wrong, strike them through and fill in the correct details in the "Amended details" column.

Particulars of a new Director must be notified on form 288a.

Name
Mark Henry RICHMOND

This is a service address for the beneficiary of a Confidentiality Order.

Address
79 New Cavendish Street
London
W1W 6XB

Date of birth 01/02/1931

Nationality British

Occupation Company Director

Name

 Tick this box if this address is a service address for the beneficiary of a Confidentiality Order granted under section 723B of the Companies Act 1985.

Address

UK Postcode L L L L L L L

Date of birth L L / L L / L L L L

Nationality _____

Occupation _____

Date of change L L / L L / L L L L

Date Mark Henry RICHMOND ceased to be director (if applicable)

 L L / L L / L L L L

> **Director**
If any of the details for this person are wrong, strike them through and fill in the correct details in the "Amended details" column.

Particulars of a new Director must be notified on form 288a.

Name
Dennis Michael John TURNER

This is a service address for the beneficiary of a Confidentiality Order.

Address
79 New Cavendish Street
London
W1W 6XB

Date of birth 04/10/1942

Nationality Canadian

Occupation Company Director

Name

 Tick this box if this address is a service address for the beneficiary of a Confidentiality Order granted under section 723B of the Companies Act 1985.

Address

UK Postcode L L L L L L L

Date of birth L L / L L / L L L L

Nationality _____

Occupation _____

Date of change L L / L L / L L L L

Date Dennis Michael John TURNER ceased to be director (if applicable)

 L L / L L / L L L L

> **Director**
If any of the details for this person are wrong, strike them through and fill in the correct details in the "Amended details" column.

Particulars of a new Director must be notified on form 288a.

Name
Martyn Douglas WILLIAMS

Address
79 New Cavendish Street
London
W1W 6XB

Date of birth 05/05/1951

Nationality British

Occupation Company Director

Name

Tick this box if this address is a service address for the beneficiary of a Confidentiality Order granted under section 723B of the Companies Act 1985.

Address

UK Postcode _ _ _ _ _

Date of birth _ _ / _ _ / _ _ _ _

Nationality _____

Occupation _____

Date of change _ _ / _ _ / _ _ _ _

Date: Martyn Douglas WILLIAMS
ceased to be director (if applicable)

 _ _ / _ _ / _ _ _ _

> **Director**
If any of the details for this person are wrong, strike them through and fill in the correct details in the "Amended details" column.

Particulars of a new Director must be notified on form 288a.

Name
Professor Seppo YLA HERTTUALA

This is a service address for the beneficiary of a Confidentiality Order.

Address
79 New Cavendish Street
London
W1W 6XB

Date of birth 05/01/1957

Nationality Finnish

Occupation Professor

Name

Tick this box if this address is a service address for the beneficiary of a Confidentiality Order granted under section 723B of the Companies Act 1985.

Address

UK Postcode _ _ _ _ _

Date of birth _ _ / _ _ / _ _ _ _

Nationality _____

Occupation _____

Date of change _ _ / _ _ / _ _ _ _

Date Professor Seppo YLA
HERTTUALA ceased to be director (if
applicable) _ _ / _ _ / _ _ _ _

Issued share capital details

> Please fill in the details of total share capital by class (eg. ordinary, preference etc) that has been issued to the company's shareholders.

Class of Share

ORDINARY

Number of shares issued

127,387,960

Aggregate Nominal Value of issued shares

£1,273,879.60

Class of Share

Number of shares issued

Aggregate Nominal Value of issued shares

Class of Share

Number of shares issued

Aggregate Nominal Value of issued shares

Class of Share

Number of shares issued

Aggregate Nominal Value of issued shares

> Please fill in the total number of issued shares and their total nominal value.

Number of shares issued

127,387,960

Aggregate Nominal Value of issued shares

£1,273,879.60

List of past and present members (Tick appropriate box)

> Please complete the required information on the attached schedules or in another format agreed by Companies House.

- There were no changes during the period
 A list of changes is enclosed
 A full list of members is enclosed

The last full list of members was received on: 31/10/2004

> **REMEMBER:**

Changes to shareholder particulars or details of shares transferred to be **completed each year**
A full list of shareholders is required with the first and every third Annual Return thereafter
List shareholders in alphabetical order or provide an index
List joint shareholders consecutively

shareholders since the last annual return.

- > Please fill in details of any persons or corporate bodies that have transferred shares since the last annual return.
- > Please use Section 4B to give details of any persons or corporate bodies who have ceased to be shareholders since the last annual return or, in the case of a first return, since the incorporation of the company.
- > Please copy this page if there is not enough space to enter all the company's current shareholders.

Shareholders details	Class and number of shares or amount of stock held	Class and number of shares or amount of stock transferred (If appropriate)	Date of registration of transfer (If appropriate)
Name _____ Address _____ _____ _____ UK Postcode _ _ _ _ _			
Name _____ Address _____ _____ _____ UK Postcode _ _ _ _ _			
Name _____ Address _____ _____ _____ UK Postcode _ _ _ _ _			
Name _____ Address _____ _____ _____ UK Postcode _ _ _ _ _			

> Please fill in details of any persons or corporate bodies who have ceased to be shareholders at the date of this return. Also, please give the dates that their shares were transferred.

> Please copy this page if there is not enough space to enter all the company's former shareholders.

Former shareholders details	Class and number of shares or amount of stock transferred	Date of registration of transfer
Name _____ Address _____ _____ _____ UK Postcode L L L L L L L L		
Name _____ Address _____ _____ _____ UK Postcode L L L L L L L L		
Name _____ Address _____ _____ _____ UK Postcode L L L L L L L L		
Name _____ Address _____ _____ _____ UK Postcode L L L L L L L L		
Name _____ Address _____ _____ _____ UK Postcode L L L L L L L L		



when you have checked all the sections of this form, please complete this page and sign the declaration below.

- > If you want to change the made up date of this annual return, please complete 2 below.

1. Declaration

- I confirm that the details in this annual return are correct as at the made-up-date (shown at 2 below). I enclose the filing fee of £30.

Signature Nick Plummer
(Director / Secretary)

Date 02/11/2005
This date must not be earlier than the return date at 2 below

What to do now

Complete this page then send the whole of the Annual Return and the declaration to the address shown at 4 below.

2. Date of this return

- This AR is made up to 31/10/2005 If you are making this return up to an earlier date, please give the date here

__ / __ / ____

Note: The form must be delivered to CH within 28 days of this date

3. Date of next return

- If you wish to change your next return to a date earlier than **31st October 2006** please give the new date here:

__ / __ / ____

4. Where to send this form

- Please return this form to:

Registrar of Companies
Companies House
Crown Way
Cardiff CF14 3UZ

OR

For members of the Hays Document
Exchange service
DX 33050 Cardiff

Have you enclosed the filing fee with the company number written on the reverse of the cheque?

Contact Address

You do not have to give any contact information below, but if you do, it will help Companies House to contact you if there is a query on the form. The contact information that you give will be visible to searchers of the public record.

Contact Name

Telephone number *inc code*

Nick Plummer
Ark Therapeutics Group plc
79 New Cavendish Street
London W1W 6XB

able

Tel: 0207 300 7722



Companies House
for the record

88(2)

Return of Allotment of Shares

Please complete in typescript, or
in bold black capitals.

CHWP000

Company Number

4313987

Company name in full

ARK THERAPEUTICS GROUP PLC

Shares allotted (including bonus shares):

Date or period during which shares were allotted <i>(If shares were allotted on one date enter that date in the "from" box)</i>	From			To		
	Day	Month	Year	Day	Month	Year
	1	1	2005			

Class of shares
(ordinary or preference etc)

ORDINARY

Number allotted

13000

Nominal value of each share

£0.01

Amount (if any) paid or due on each
share *(including any share premium)*

60p

List the names and addresses of the allottees and the number of shares allotted to each overleaf

If the allotted shares are fully or partly paid up otherwise than in cash please state:

% that each share is to be
treated as paid up

--	--	--

Consideration for which
the shares were allotted

*(This information must be supported by
the duly stamped contract or by the duly
stamped particulars on Form 88(3) if the
contract is not in writing)*

When you have completed and signed the form send it to
the Registrar of Companies at:

Companies House receipt date barcode
*This form has been provided free of charge
by Companies House.*

Companies House, Crown Way, Cardiff CF14 3UZ
For companies registered in England and Wales

DX 33050 Cardiff

Companies House, 37 Castle Terrace, Edinburgh EH1 2EB
For companies registered in Scotland

DX 235
Edinburgh

Shareholder details	Shares and share class allotted	
Name PERSHING KEEN NOMINEES LIMITED <hr/> Address PARTICIPANT ID 601 MEMBER ACCOUNT LDCLT CAPSTAN HSE, ONE CLOVE CRESCENT, EAST INDIA DOCK, LONDON <hr/> UK Postcode E 1 4 2 B H	Class of shares allotted <hr/> ORDINARY <hr/>	Number allotted <hr/> 13,000 <hr/>
Name <hr/> Address <hr/> <hr/> UK Postcode L L L L L L L L	Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>
Name <hr/> Address <hr/> <hr/> UK Postcode L L L L L L L L	Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>
Name <hr/> Address <hr/> <hr/> UK Postcode L L L L L L L L	Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>
Name <hr/> Address <hr/> <hr/> UK Postcode L L L L L L L L	Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>

Please enter the number of continuation sheets (if any) attached to this form

Signed

N.P. Plummer

Date

17/11/2005

~~Director / secretary / administrator / administrative receiver / receiver manager / receiver~~

Please delete as appropriate

Please give the name, address, telephone number and, if available, a DX number and Exchange of the person Companies House should contact if there is any query.

Nick Plummer
79 New Cavendish Street
London
W1W 6XB

Tel: 0207 388 7722



Companies House
for the record

88(2)

Return of Allotment of Shares

Please complete in typescript, or
in bold black capitals.

CHWP000

Company Number

4313987

Company name in full

ARK THERAPEUTICS GROUP PLC

Shares allotted (including bonus shares):

Date or period during which shares were allotted <i>(If shares were allotted on one date enter that date in the "from" box)</i>	From			To		
	Day	Month	Year	Day	Month	Year
	1	1	2005			

Class of shares
(ordinary or preference etc)

ORDINARY

Number allotted

25000

Nominal value of each share

£0.01

Amount (if any) paid or due on each
share *(including any share premium)*

60p

List the names and addresses of the allottees and the number of shares allotted to each overleaf

If the allotted shares are fully or partly paid up otherwise than in cash please state:

% that each share is to be
treated as paid up

--	--	--

Consideration for which
the shares were allotted

*(This information must be supported by
the duly stamped contract or by the duly
stamped particulars on Form 88(3) if the
contract is not in writing)*

When you have completed and signed the form send it to
the Registrar of Companies at:

Companies House receipt date barcode
*This form has been provided free of charge
by Companies House.*

Companies House, Crown Way, Cardiff CF14 3UZ
For companies registered in England and Wales

DX 33050 Cardiff

Companies House, 37 Castle Terrace, Edinburgh EH1 2EB
For companies registered in Scotland

DX 235
Edinburgh

Shareholder details	Shares and share class allotted	
Name PERSHING KEEN NOMINEES LIMITED <hr/> Address PARTICIPANT ID 601 MEMBER ACCOUNT LDCLT CAPSTAN HSE, ONE CLOVE CRESCENT, EAST INDIA DOCK, LONDON <hr/> UK Postcode E 1 4 2 B H	Class of shares allotted <hr/> ORDINARY <hr/>	Number allotted <hr/> 25,000 <hr/>
Name <hr/> Address <hr/> <hr/> UK Postcode L L L L L L L	Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>
Name <hr/> Address <hr/> <hr/> UK Postcode L L L L L L L	Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>
Name <hr/> Address <hr/> <hr/> UK Postcode L L L L L L L	Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>
Name <hr/> Address <hr/> <hr/> UK Postcode L L L L L L L	Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>

Please enter the number of continuation sheets (if any) attached to this form

Signed N. Plummer Date 17/11/2005
director / secretary / administrator / administrative receiver / receiver manager / receiver Please delete as appropriate

Please give the name, address, telephone number and, if available, a DX number and Exchange of the person Companies House should contact if there is any query.

Nick Plummer
79 New Cavendish Street
London
W1W 6XB

Tel: 0207 388 7722



Companies House
for the record

88(2)

Return of Allotment of Shares

Please complete in typescript, or
in bold black capitals.

CHWP000

Company Number

Company name in full

Shares allotted (including bonus shares):

Date or period during which shares were allotted

(If shares were allotted on one date enter that date in the "from" box)

From			To		
Day	Month	Year	Day	Month	Year
1	4	1 1 2 0 0 5			

Class of shares <i>(ordinary or preference etc)</i>	ORDINARY		
Number allotted	2750		
Nominal value of each share	£0.01		
Amount (if any) paid or due on each share <i>(including any share premium)</i>	50p		

List the names and addresses of the allottees and the number of shares allotted to each overleaf

If the allotted shares are fully or partly paid up otherwise than in cash please state:

% that each share is to be treated as paid up

--	--	--

Consideration for which the shares were allotted

(This information must be supported by the duly stamped contract or by the duly stamped particulars on Form 88(3) if the contract is not in writing)

When you have completed and signed the form send it to the Registrar of Companies at:

Companies House receipt date barcode

This form has been provided free of charge by Companies House.

Companies House, Crown Way, Cardiff CF14 3UZ
For companies registered in England and Wales

DX 33050 Cardiff

Companies House, 37 Castle Terrace, Edinburgh EH1 2EB
For companies registered in Scotland

DX 235
Edinburgh

Shareholder details	Shares and share class allotted	
Name PERSHING KEEN NOMINEES LIMITED	Class of shares allotted	Number allotted
Address PARTICIPANT ID 601 MEMBER ACCOUNT LDCLT CAPSTAN HSE, ONE CLOVE CRESCENT, EAST INDIA DOCK, LONDON	ORDINARY	2,750
UK Postcode E 1 4 2 B H		
Name	Class of shares allotted	Number allotted
Address		
UK Postcode		
Name	Class of shares allotted	Number allotted
Address		
UK Postcode		
Name	Class of shares allotted	Number allotted
Address		
UK Postcode		
Name	Class of shares allotted	Number allotted
Address		
UK Postcode		

Please enter the number of continuation sheets (if any) attached to this form

Signed

N. Plummer

Date

18/11/2005

~~director~~ secretary administrator / administrative receiver / receiver manager / receiver

Please delete as appropriate

Please give the name, address, telephone number and, if available, a DX number and Exchange of the person Companies House should contact if there is any query.

Nick Plummer
79 New Cavendish Street
London
W1W 6XB

Tel: 0207 388 7722



Companies House

for the record

88(2)

Return of Allotment of Shares

Please complete in typescript, or in bold black capitals.

CHWP000

Company Number

4313987

Company name in full

ARK THERAPEUTICS PLC

Shares allotted (including bonus shares):

Date or period during which shares were allotted <i>(If shares were allotted on one date enter that date in the "from" box)</i>	From			To										
	Day	Month	Year	Day	Month	Year								
	3	0	1	1	2	0	0	5						

Class of shares

(ordinary or preference etc)

ORDINARY

Number allotted

33099

Nominal value of each share

£0.01

Amount (if any) paid or due on each share
(including any share premium)

List the names and addresses of the allottees and the number of shares allotted to each overleaf

If the allotted shares are fully or partly paid up otherwise than in cash please state:

% that each share is to be treated as paid up

Consideration for which the shares were allotted

(This information must be supported by the duly stamped contract or by the duly stamped particulars on Form 88(3) if the contract is not in writing)

When you have completed and signed the form send it to the Registrar of Companies at:

Companies House receipt date barcode
This form has been provided free of charge by Companies House.

Companies House, Crown Way, Cardiff CF14 3UZ
For companies registered in England and Wales

DX 33050 Cardiff

Companies House, 37 Castle Terrace, Edinburgh EH1 2EB
For companies registered in Scotland

DX 235
Edinburgh

Shareholder details	Shares and share class allotted	
Name PERSHING KEEN NOMINEES LIMITED <hr/> Address PARTICIPANT ID 601 MEMBER ACCOUNT LDCLT CAPSTAN HSE, ONE CLOVE CRESCENT, EAST INDIA DOCK, LONDON <hr/> UK Postcode E 1 4 L 2 B H	Class of shares allotted <hr/> ORDINARY <hr/>	Number allotted <hr/> 33,099 <hr/>
Name <hr/> Address <hr/> <hr/> UK Postcode L L L L L L L L	Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>
Name <hr/> Address <hr/> <hr/> UK Postcode L L L L L L L L	Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>
Name <hr/> Address <hr/> <hr/> UK Postcode L L L L L L L L	Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>
Name <hr/> Address <hr/> <hr/> UK Postcode L L L L L L L L	Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>

Please enter the number of continuation sheets (if any) attached to this form

Signed

Nick Plummer
~~director / secretary / administrator / administrative receiver / receiver manager / receiver~~

Date

06/12/2005

Please delete as appropriate

Please give the name, address, telephone number and, if available, a DX number and Exchange of the person Companies House should contact if there is any query.

<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	Nick Plummer 79 New Cavendish Street London W1W 6XB E	<hr/> <hr/> <hr/> <hr/>
--	---	-------------------------

Tel: 0207 388 7722

Company Ark Therapeutics Group PLC
TIDM AKT
Headline Grant for New Facility
Released 07:00 03-Nov-05
Number 5692T

Ark Therapeutics receives €2.19 million grant for new manufacturing facility in Finland

Largest ever grant awarded to biotechnology company by TE-Centre

London, UK, 3 November 2005: Ark Therapeutics Group plc ("Ark") announces today that it has been awarded a grant of €2.19 million to support the Company's investment in a new GMP manufacturing facility (MT4) in Kuopio, Finland. The grant is from The Employment and Economic Development Centre of Finland ("TE-Centre") and is believed to be the largest awarded to the Biotech-Pharma Industry by the TE-Centre since its foundation in 2000.

Ark currently has a unique cGMP facility in Kuopio which is currently being prepared for commercial-scale manufacture of Cerepro™ (gene-based medicine for treatment of brain cancer). The new MT4 facility will significantly increase Ark's manufacturing capacity and scope in the gene-based medicines where the Company is one of the world's leaders. The expanded capabilities will allow Ark to produce commercial-scale cGMP medicines for Cerepro™ and its other lead gene-based medicine Trinam® (haemodialysis access graft surgery), and also to manufacture trials supplies for its earlier pipeline opportunities as they move from preclinical into Phase I human trials in compliance with the new 2005 European pharmaceutical legislation.

Work on MT4 has already commenced and the Company expects it to be operational for validation to commence towards the end of 2007. The TE-Centre has a successful track record in promoting the development of key sectors in Finland, working with the European Union, which will contribute 50% of the grant awarded to Ark from the European Regional Development Fund.

Dr Nigel Parker, Chief Executive Officer of Ark, commented: "We have a very constructive relationship with the national authorities in Finland who fully understand our commitment to the sector and to developing this unique expertise in Finland. We are very pleased to have been awarded this significant grant."

For further information:

Ark Therapeutics Group plc
Dr Nigel Parker, CEO
Martyn Williams, CFO

Tel: + 44 (0)20 7388 7722

Financial Dynamics
David Yates
Davina Langdale

Tel: +44 (0)20 7831 3113

Notes to Editors

Ark Therapeutics Group plc

Ark is an emerging healthcare group (the "Group") with one product introduced into hospitals and three further lead products in late stage clinical development. Capitalising on over ten years of research in vascular biology and gene-based medicine, Ark has a balanced portfolio of proprietary healthcare products targeted at specific unmet clinical needs within vascular disease and cancer. These are large and growing markets, where opportunities exist for effective new products to generate significant revenues.

Ark's products are sourced from related but largely non-dependent technologies within the Group and have been selected to enable Ark to take each product through development and to benefit from Orphan Drug Status and/or Fast Track Designation, as appropriate. The Group generally retains ownership of its product candidates throughout clinical development. Ark has secured patents or has patent applications pending for all its lead products in principal pharmaceutical markets and retains the right to market its lead products in the key North American and European markets.

Ark has its origins in businesses established in the mid-1990s by Professor John Martin and Mr Stephen Barker of University College London and Professor Seppo Ylä-Herttuala of the AI Virtanen Institute at the University of Kuopio, Finland, all of whom play leading roles in the Company's research and development programmes.

TE-Centre

combined their regional efforts in the Employment and Economic Development Centres (TE Centres). A TE-Centre across Finland provide a comprehensive range of advisory and development services for businesses, entrepreneurs and private individuals. The three main tasks of the TE-Centre are to 1) support and advise small and medium-sized enterprises at the various stages of their life cycles, 2) promote technological development in enterprises and assist in matters associated with export activities and internationalisation and 3) implement regional labour policies.

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products and services), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Ark's funding requirements, regulatory approvals, clinical trials, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.

END

Close

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

©2005 London Stock Exchange plc. All rights reserved

Regulatory Announcement

Go to market news section



Company Ark Therapeutics Group PLC
TIDM AKT
Headline Blocklisting Interim Review
Released 09:00 05-Dec-05
Number 0871V

RNS Number:0871V
Ark Therapeutics Group PLC
05 December 2005

BLOCKLISTING SIX MONTHLY REVIEW

1. NAME OF COMPANY: ARK THERAPEUTICS GROUP PLC

2. NAME OF SCHEME: ARK THERAPEUTICS GROUP UNAPPROVED SHARE OPTION SCHEME

3. PERIOD OF RETURN: FROM: 9/6/2005 TO: 2/12/2005

4. NUMBER AND CLASS OF SHARE(S)
(AMOUNT OF STOCK/DEBT SECURITY)
NOT ISSUED UNDER SCHEME
AT END OF THE LAST PERIOD: 1,500,000 ORDINARY SHARES OF 1 PENCE EACH

5. NUMBER OF SHARES ISSUED/ALLOTTED
UNDER SCHEME DURING PERIOD: 592,599

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED
AT END OF PERIOD: 907,401

7. NUMBER AND CLASS OF SHARE(S)
(AMOUNT OF STOCK/DEBT SECURITIES)
ORIGINALLY LISTED AND THE DATE OF ADMISSION:

126,220,994 ORDINARY SHARES ADMITTED TO LISTING ON 8/3/2004

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD
IN ORDER FOR US TO UPDATE OUR RECORDS.

127,461,809

CONTACT FOR QUERIES

NAME: NICK PLUMMER
TELEPHONE: 0207 388 7722

END

Close

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

©2005 London Stock Exchange plc. All rights reserved

Company Ark Therapeutics Group PLC
TIDM AKT
Headline Blocklisting Interim Review
Released 09:00 05-Dec-05
Number 0868V

RNS Number:0868V
Ark Therapeutics Group PLC
05 December 2005

SCHEDULE 5

BLOCKLISTING SIX MONTHLY RETURN

1. Name of company

Ark Therapeutics Group plc

2. Name of scheme

Ark Therapeutics Group Enterprise Management Incentive Share Option Plan

3. Period of return

From 9/6/2005 to 2/12/2005

4. Number and class of shares (a) amount of stock/debt security) not issued under scheme

500,000 ordinary shares of 1 pence each

5. Number of shares Issued/allotted under scheme during period

222,984

6. Balance under scheme not yet issued/allotted at end of period

277,016

7. Number and class of share(s) (amount of stock/debt securities) originally listed and the date of admission

126,220,994 ordinary shares admitted to listing on 8/3/2004

Please confirm total number of shares in issue at the end of the period in order for us to update our records:

127,461,809

Contact for queries: Nick Plummer, Ark Therapeutics Group plc, 79 New Cavendish Street, London W1W 6XB

Telephone: 0207 388 7722

Person making return:

Name: Nick Plummer

Position: Company Secretary

Signature:

This information is provided by RNS
The company news service from the London Stock Exchange

END

Close

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

©2005 London Stock Exchange plc. All rights reserved